With authoritative coverage of rare and common hemostatic disorders, Consultative Hemostasis and Thrombosis, 4th Edition, keeps you both up to date with all that’s new in this fast-moving field as well as reviewing background and development and citing pertinent classical literature. Broad differential diagnoses are provided, underscoring the editors’ position that correct treatment begins with correct diagnosis. This trusted resource by Drs. Craig S. Kitchens, Craig M. Kessler, Barbara A. Konkle, Michael B. Streiff, and David A. Garcia is designed for rapid reference and critical decision making at the point of care.
1. Introduction - p. 1 2. 1 The Consultative Process - p. 2 3. 2 A Systematic Approach to the Bleeding Patient - p. 17 4. Part II Hemorrhagic Processes - p. 37 5. Introduction - p. 38 6. 3 Hemophilia A and Hemophilia B - p. 39 7. 4 Less Common Congenital Disorders of Hemostasis - p. 59 8. 5 Acquired Coagulation Disorders Caused by Inhibitors - p. 80 9. 6 von Willebrand Disease - p. 93 10. 7 General Aspects of Thrombocytopenia, Platelet Transfusions, and Thrombopoietic Growth Factors - p. 108 11. 8 Immune Thrombocytopenia - p. 127 12. 9 Congenital and Acquired Disorders of Platelet Function and Number - p. 145 13. 10 Purpura and Other Hematovascular Disorders - p. 167 14. 11 Hereditary Hemorrhagic Telangiectasia - p. 190 15. 12 Disseminated Intravascular Coagulation - p. 207 16. 13 Crosstalk of Inflammation and Coagulation in Infectious Disease and Their Roles in Disseminated Intravascular Coagulation - p. 226 17. Part III Thrombotic Processes - p. 240 18. Introduction - p. 241 19. 14 Thrombophilia - p. 242 20. 15 Pediatric Aspects of Thrombophilia - p. 266 21. 16 Prevention and Treatment of Venous Thromboembolism - p. 273 22. 17 Venous Thromboses at Unusual Sites - p. 300 23. Abstract - p. 300 24. Historical Aspects - p. 301 25. Importance to The Patient and The Clinician - p. 300.e1 26. Intra-Abdominal Thrombosis - p. 302 27. Cerebral Venous Thrombosis - p. 312 28. Retinal Vein or Artery Thrombosis - p. 316 29. Upper Extremity Thrombosis - p. 317 30. Lemierre Syndrome - p. 320 31. Cutaneous Microvascular Thrombosis (Purpura Fulminans) - p. 320 32. Ovarian Vein Thrombosis - p. 322 33. Thrombosis at Other Sites - p. 323 34. Consultation Considerations - p. 324 35. Laboratory Evaluation - p. 325 36. Cost Containment Issues - p. 325 37. References - p. 325 38. 18 Postthrombotic Syndrome - p. 338 39. 19 Thrombocytosis - p. 346 40. 20 Antiphospholipid Syndrome - p. 374 41. 21 Antiplatelet Therapy in Cardiovascular Medicine - p. 396 42. 22 Nonarteriosclerotic Disorders of the Arterial System - p. 415 43. 23 Thrombosis and Cancer - p. 430 44. 24 Thrombotic Thrombocytopenic Purpura and Related Thrombotic Microangiopathies - p. 448 45. 25 Complement-Mediated Coagulation Disorders - p. 473 46. 26 Heparin-Induced Thrombocytopenia - p. 491 47. Abstract: - p. 491 48. Historical Overview - p. 492 49. Terminology - p. 492 50. Definition - p. 491.e1 51. Pathogenesis - p. 491.e1 52. Frequency - p. 494 53. Clinical Features - p. 496 54. Differential Diagnosis - p. 500 55. Clinical Scoring Systems - p. 501 56. Laboratory Testing - p. 501 57. Clinical-Treatment Interface: Delayed-Onset Heparin-Induced Thrombocytopenia and Treatment Implications - p. 505 58. Treatment of Patients With Thrombosis Associated With Heparin-Induced Thrombocytopenia - p. 505 59. Caveats in the Management of Heparin-Induced Thrombocytopenia - p. 511 60. Treatment of Patients With Isolated Heparin-Induced Thrombocytopenia - p. 513 61. Reexposure to Heparin After Previous Heparin-Induced Thrombocytopenia - p. 513 62. Specialized Clinical Situations - p. 514 63. Prevention of Heparin-Induced Thrombocytopenia - p. 516 64. References - p. 517 65. Part IV Therapeutic Agents - p. 527 66. Introduction - p. 528 67. 27 Parenteral Antithrombotic Agents - p. 529 68. 28 Blood Component and Pharmacologic Therapy for Hemostatic Disorders - p. 540 69. 29 Therapeutic Apheresis—Applications for Hemorrhagic and Thrombotic Disorders - p. 573 70. 30 Use of Vena Cava Filters and Venous Access Devices - p. 594 71. Abstract - p. 594 72. Vena Cava Filters - p. 595 73. Thrombosis Related to Venous Access Devices - p. 613 74. References - p. 622 75. Part V Issues Specific to Women - p. 635 76. Introduction - p. 636 77. 31 Thrombotic Risk of Contraceptives and Other Hormonal Therapies - p. 637 78. 32 Bleeding and the Management of Hemorrhagic Disorders in Pregnancy - p. 651 79. 33 Thrombophilia in Pregnancy - p. 665 80. Part VI Special Issues - p. 694 81. Introduction - p. 695 82. 34 Surgery and Hemostasis - p. 696 83. 35 Anticoagulation in the Perioperative Period - p. 721 84. 36 Understanding and Managing the Coagulopathy of Liver Disease - p. 734 85. 37 Outpatient Oral Anticoagulant Therapy - p. 747 86. 38 Hematologic Interventions for Acute Central Nervous System Disease - p. 778 87. 39 Paradoxical Embolic Stroke - p. 802 88. 40 Hemorrhage Control and Thrombosis Following Severe Injury - p. 811 89. 41 Hemostatic Aspects of Sickle Cell Disease - p. 819 90. Index - p. 843
No hay muestra disponible
No hay ficha técnica disponible
With authoritative coverage of rare and common hemostatic disorders, Consultative Hemostasis and Thrombosis, 4th Edition, keeps you both up to date with all that’s new in this fast-moving field as well as reviewing background and development and citing pertinent classical literature. Broad differential diagnoses are provided, underscoring the editors’ position that correct treatment begins with correct diagnosis. This trusted resource by Drs. Craig S. Kitchens, Craig M. Kessler, Barbara A. Konkle, Michael B. Streiff, and David A. Garcia is designed for rapid reference and critical decision making at the point of care.
1. Introduction - p. 1 2. 1 The Consultative Process - p. 2 3. 2 A Systematic Approach to the Bleeding Patient - p. 17 4. Part II Hemorrhagic Processes - p. 37 5. Introduction - p. 38 6. 3 Hemophilia A and Hemophilia B - p. 39 7. 4 Less Common Congenital Disorders of Hemostasis - p. 59 8. 5 Acquired Coagulation Disorders Caused by Inhibitors - p. 80 9. 6 von Willebrand Disease - p. 93 10. 7 General Aspects of Thrombocytopenia, Platelet Transfusions, and Thrombopoietic Growth Factors - p. 108 11. 8 Immune Thrombocytopenia - p. 127 12. 9 Congenital and Acquired Disorders of Platelet Function and Number - p. 145 13. 10 Purpura and Other Hematovascular Disorders - p. 167 14. 11 Hereditary Hemorrhagic Telangiectasia - p. 190 15. 12 Disseminated Intravascular Coagulation - p. 207 16. 13 Crosstalk of Inflammation and Coagulation in Infectious Disease and Their Roles in Disseminated Intravascular Coagulation - p. 226 17. Part III Thrombotic Processes - p. 240 18. Introduction - p. 241 19. 14 Thrombophilia - p. 242 20. 15 Pediatric Aspects of Thrombophilia - p. 266 21. 16 Prevention and Treatment of Venous Thromboembolism - p. 273 22. 17 Venous Thromboses at Unusual Sites - p. 300 23. Abstract - p. 300 24. Historical Aspects - p. 301 25. Importance to The Patient and The Clinician - p. 300.e1 26. Intra-Abdominal Thrombosis - p. 302 27. Cerebral Venous Thrombosis - p. 312 28. Retinal Vein or Artery Thrombosis - p. 316 29. Upper Extremity Thrombosis - p. 317 30. Lemierre Syndrome - p. 320 31. Cutaneous Microvascular Thrombosis (Purpura Fulminans) - p. 320 32. Ovarian Vein Thrombosis - p. 322 33. Thrombosis at Other Sites - p. 323 34. Consultation Considerations - p. 324 35. Laboratory Evaluation - p. 325 36. Cost Containment Issues - p. 325 37. References - p. 325 38. 18 Postthrombotic Syndrome - p. 338 39. 19 Thrombocytosis - p. 346 40. 20 Antiphospholipid Syndrome - p. 374 41. 21 Antiplatelet Therapy in Cardiovascular Medicine - p. 396 42. 22 Nonarteriosclerotic Disorders of the Arterial System - p. 415 43. 23 Thrombosis and Cancer - p. 430 44. 24 Thrombotic Thrombocytopenic Purpura and Related Thrombotic Microangiopathies - p. 448 45. 25 Complement-Mediated Coagulation Disorders - p. 473 46. 26 Heparin-Induced Thrombocytopenia - p. 491 47. Abstract: - p. 491 48. Historical Overview - p. 492 49. Terminology - p. 492 50. Definition - p. 491.e1 51. Pathogenesis - p. 491.e1 52. Frequency - p. 494 53. Clinical Features - p. 496 54. Differential Diagnosis - p. 500 55. Clinical Scoring Systems - p. 501 56. Laboratory Testing - p. 501 57. Clinical-Treatment Interface: Delayed-Onset Heparin-Induced Thrombocytopenia and Treatment Implications - p. 505 58. Treatment of Patients With Thrombosis Associated With Heparin-Induced Thrombocytopenia - p. 505 59. Caveats in the Management of Heparin-Induced Thrombocytopenia - p. 511 60. Treatment of Patients With Isolated Heparin-Induced Thrombocytopenia - p. 513 61. Reexposure to Heparin After Previous Heparin-Induced Thrombocytopenia - p. 513 62. Specialized Clinical Situations - p. 514 63. Prevention of Heparin-Induced Thrombocytopenia - p. 516 64. References - p. 517 65. Part IV Therapeutic Agents - p. 527 66. Introduction - p. 528 67. 27 Parenteral Antithrombotic Agents - p. 529 68. 28 Blood Component and Pharmacologic Therapy for Hemostatic Disorders - p. 540 69. 29 Therapeutic Apheresis—Applications for Hemorrhagic and Thrombotic Disorders - p. 573 70. 30 Use of Vena Cava Filters and Venous Access Devices - p. 594 71. Abstract - p. 594 72. Vena Cava Filters - p. 595 73. Thrombosis Related to Venous Access Devices - p. 613 74. References - p. 622 75. Part V Issues Specific to Women - p. 635 76. Introduction - p. 636 77. 31 Thrombotic Risk of Contraceptives and Other Hormonal Therapies - p. 637 78. 32 Bleeding and the Management of Hemorrhagic Disorders in Pregnancy - p. 651 79. 33 Thrombophilia in Pregnancy - p. 665 80. Part VI Special Issues - p. 694 81. Introduction - p. 695 82. 34 Surgery and Hemostasis - p. 696 83. 35 Anticoagulation in the Perioperative Period - p. 721 84. 36 Understanding and Managing the Coagulopathy of Liver Disease - p. 734 85. 37 Outpatient Oral Anticoagulant Therapy - p. 747 86. 38 Hematologic Interventions for Acute Central Nervous System Disease - p. 778 87. 39 Paradoxical Embolic Stroke - p. 802 88. 40 Hemorrhage Control and Thrombosis Following Severe Injury - p. 811 89. 41 Hemostatic Aspects of Sickle Cell Disease - p. 819 90. Index - p. 843
No hay muestra disponible
No hay ficha técnica disponible
